La Jolla, CA, June 5, 2008 - Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first-in-class, small molecule cancer therapeutics, announced today that it successfully closed its Series A-3 Preferred Stock Financing allowing it to expand its team following its relocation from Pasadena, CA to La Jolla, CA.
Download/view the full press release as a PDF file
Pasadena, CA, February 26, 2007 - Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first in class small molecule cancer therapeutics, announced today that it has licensed its drug candidate NVX-207 to AOP Orphan Pharmaceuticals AG. The exclusive but restricted license will enable AOP Orphan Pharmaceuticals to develop and commercialize NVX-207 in human orphan designations in all territories outside the United States. Financial terms of the agreement were not disclosed.